
Weight loss jabs can reduce the risk of a heart attack or stroke in obese people with cardiovascular disease by a fifth, researchers say.
Pharmaceutical company Novo Nordisk conducted a five-year study of semaglutide, which is sold as Wegovy.

Weight loss jabs can reduce the risk of a heart attack or stroke in obese people with cardiovascular disease by a fifth, researchers say.
Pharmaceutical company Novo Nordisk conducted a five-year study of semaglutide, which is sold as Wegovy.